April 17, 2017
OncoMed’s lung cancer drug fails mid-stage study, shares tumble
OncoMed Pharmaceuticals Inc said on Monday its experimental lung cancer drug failed a mid-stage study, sending its shares tumbling 30 percent in premarket trading.